- Company
- Hemophilia drug Hemlibra’s sales rise twofold with reimb
- by Chon, Seung-Hyun Aug 31, 2023 05:25am
- Sales of JW Pharmaceutical’s hemophilia drug ‘Hemlibra’ have surged recently. The reimbursement extensions that had been made for the drug in May had increased the number of eligible patients, raising sales by over twofold. According to the pharmaceuticals research institution IQVIA, Hemlibra’s sales in 1H this year were KRW 5.7 billion,
- Company
- The obesity market doubled in 5 years
- by Chon, Seung-Hyun Aug 31, 2023 05:25am
- Saxenda widens the gap with Qsymia. The imminent release of large products such as Wegovy. The domestic obesity market is expanding at a rapid pace. As demand for weight loss through pharmaceuticals increases, the market size has more than doubled in the past five years. Saxenda's quarterly sales exceeded 20 billion won and its market share a
- Company
- Reimb for the petitioned ADC drug Enhertu unclear
- by Eo, Yun-Ho Aug 31, 2023 05:25am
- Reimbursement discussions for the anticancer drug ‘Enhertu’ that received 50,000 consents in a national petition are making slow progress. Daiichi Sankyo Korea’s HER2-directed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), which finally passed the Health Insurance Review and Assessment Service’s Cancer Disease Delibera
- Company
- Leclaza’s cumulative sales reach KRW 30 bil in 2 yrs
- by Chon, Seung-Hyun Aug 30, 2023 05:32am
- Yuhan Corp’s new anticancer drug, ‘Leclaza’ is gradually expanding its influence in the domestic market. The drug exceeded KRW 30 billion in cumulative sales in only 2 years since its domestic release. Prescriptions are also expected to increase further if the company receives reimbursement for its newly added indication as a first-line treat
- Company
- Sales of Taxol & Genexol rise together
- by Kim, Jin-Gu Aug 30, 2023 05:31am
- Sales of Taxol and Genexol, which contain paclitaxel, rose together in 1H this year. After the sales companies for the two drugs were switched, competition between Boryeong, which has Taxol, and HK Inno.N, which owns Genexol, have been intensifying. According to the industry research institution IQVIA on the 30th, Taxol posted sales of
- Company
- Perjeta and Herceptin combination drug, Phesgo
- by Eo, Yun-Ho Aug 30, 2023 05:31am
- Phesgo, a subcutaneous injection-type combination of Perjeta and Herceptin, challenges insurance coverage registration. As a result of the coverage, Phesgo of Roche Korea is presented to the Cancer Disease Review Committee of the HIRA today (30th). This is the first case of an improved anti-cancer biobetter. Biobetter refers to drugs reco
- Company
- Keytruda posts sales of KRW 183.8 bil in 1H...unrivaled lead
- by Chon, Seung-Hyun Aug 29, 2023 05:28am
- The immuno-oncology drug Keytruda’s sales have been skyrocketing in the domestic drug market. In the first half of the year alone, the drug posted sales of over KRW 200 billion and secured its unrivaled lead in the market. The drug’s sales have been rising more steeply after the drug’s reimbursement was extended as first-line therapy last yea
- Company
- The synergy between technology and sales force
- by Chon, Seung-Hyun Aug 29, 2023 05:28am
- Domestically developed biosimilar products are prominent in the large anticancer drug Asastin market. Samsungbioepis' Onbevzi exceeded 10 billion won in quarterly sales in the first two years of its release, showing a 35% share. It is said that Boryung, which was the first biosimilar to enter the market and has differentiated strengths in antica
- Company
- Verquvo busy securing prescriptions in KOR with reimb
- by Eo, Yun-Ho Aug 29, 2023 05:28am
- The new heart failure drug ‘Verquvo’ is busy securing prescriptions in Korea with its reimbursement listing. According to industry sources, Bayer Korea’s soluble Guanylate Cyclase (sGC) stimulator Verquvo (Vericiguat)’ passed the drug committees of Korea Anam Hospital, Chung-Ang University Gwangmyeong Hospital, Seoul National Universi
- Company
- Price negotiation period for Spinraza and Evrysdi extended
- by Eo, Yun-Ho Aug 28, 2023 05:21am
- The companies of the spinal muscular atrophy (SMA) treatments ‘Spinraza’ and ‘Evrysdi’ failed to conclude drug pricing negotiations for their drugs within the deadline and began extended negotiations. As a result, Spinraza reimbursement extension and Evrysdi’s new listing will only be possible in October at the earliest. Accordi
